Boehringer
Boehringer’s Syrum Facebook game launch date released
August 22, 2012Medical Communications Boehringer, Facebook, Syrum
Boehringer Ingelheim has announced the launch date of its social media game Syrum. John Pugh, Boehringer’s director of digital communications …
Boehringer posts strong financials
August 16, 2012Sales and Marketing AMNOG, Boehringer, COPD, Spiriva
Boehringer Ingelheim has seen steady growth in the first half of 2012, but warns that the next six months may …
Boehringer collaborates for online ‘beyond pill’ plan
July 11, 2012Medical Communications Boehringer, diabetes, digital, healthrageous
Boehringer Ingelheim is collaborating with US digital health specialist Healthrageous on a scheme to help type II diabetes sufferers manage …
Priority review for Xarelto’s new indications
July 10, 2012Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Eliquis, FDA, Janssen, Pradaxa, Xarelto
Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …
Boehringer collaborates with Havard
July 9, 2012Research and Development, Sales and Marketing Boehringer, Havard, oncology, research deal
Boehringer Ingelheim has established a translational research collaboration with the presidents and fellows of Harvard College. The aim of the …
Boehringer seeks NHS partners for COPD campaign
June 1, 2012Medical Communications, Sales and Marketing Boehringer, COPD, disease awareness campaign
Boehringer is seeking NHS partners for its COPD campaign: ‘Know it. Check it. Treat it.’ The campaign aims to raise …
European OK for Pradaxa, but more details required
May 29, 2012Research and Development, Sales and Marketing Boehringer, CHMP, EMA, Europe, Pradaxa
The European Medicines Agency says that Boehringher’s Pradaxa can stay on the market, but will need more safety information. The …
Boehringer’s COPD drug passes hurdle
May 23, 2012Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol
Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial. The manufacturer wants the …
Gamification and online communities – what can pharma do?
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Facebook, Gamification, Syrum, digital marketing
Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This new …
Boehringer expands manufacturing in China
December 15, 2011Manufacturing and Production Boehringer, China, manufacturing
Boehringer Ingelheim plans to invest €50 million in its manufacturing plant in Shanghai as part of a drive to increase …
Boehringer signs away HIV rights to focus on hep C
October 7, 2011Research and Development Boehringer, Gilead, HIV, hepatitis C
Boehringer Ingelheim has signed a deal giving Gilead Sciences exclusive worldwide rights to a major part of its HIV portfolio. …
Boehringer to create biosimilars division
September 27, 2011Research and Development Boehringer, biosimilars
Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that …
Boehringer censured over Pradaxa marketing
September 23, 2011Medical Communications ABPI Code of Practice, Boehringer
Boehringer Ingelheim has been heavily censured by the body which enforces the ABPI’s Code of Practice for the content of …
Boehringer’s Trajenta launched in the UK
September 20, 2011Sales and Marketing Boehringer, Trajenta, diabetes
Boehringer Ingelheim has launched its new diabetes drug Trajenta in the UK, with a price tag to match its rival …
Boehringer expands afatinib breast cancer trials
August 31, 2011Research and Development Boehringer, afatinib
Boehringer Ingelheim has begun two new phase II trials of its investigational cancer drug afatinib. The studies will cover afatinib’s …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
